Meta-Analysis of Sulfonylurea Therapy on Long-Term Risk of Mortality and Cardiovascular Events Compared to Other Oral Glucose-Lowering Treatments

Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial

(2017) Olga Vaccaro et al.   Lancet Diabetes & Endocrinology

Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®)

(2015) Nikolaus Marx et al.   Diabetes & Vascular Disease Research

Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial

(2014) Benjamin M. Scirica et al.   CIRCULATION

Should Sulfonylureas Remain an Acceptable First-Line Add-on to Metformin Therapy in Patients With Type 2 Diabetes? Yes, They Continue to Serve Us Well!: Table 1

(2014) Martin J. Abrahamson   DIABETES CARE

Should Sulfonylureas Remain an Acceptable First-Line Add-on to Metformin Therapy in Patients With Type 2 Diabetes? No, It’s Time to Move On!

(2014) Saul Genuth   DIABETES CARE

Bayesian Methods for Evidence Evaluation

(2013) Steven N. Goodman   CIRCULATION

Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

(2013) D. M. Nathan et al.   DIABETES CARE